Celerus Diagnostics

About Celerus Diagnostics

Celerus Diagnostics, established in 2004, was a developer of diagnostic technologies aimed at the anatomic pathology market. The company was founded by Page Erickson and was headquartered in Carpinteria, California.

The firm's core business was centered on enhancing the speed and efficiency of cancer diagnosis. It targeted anatomic pathology laboratories as its primary clients, providing them with tools to deliver faster results to clinicians. The business model appears to have been based on the sale of its proprietary diagnostic systems and related accessories and antibodies.

Celerus Diagnostics' flagship product was the Wave System, a semi-automated platform designed for rapid immunohistochemistry (IHC). This system was engineered to significantly reduce the time required for IHC test results, delivering them in as little as 15 minutes on certain tissue sections. The benefit for surgeons and patients was the potential to receive critical diagnostic information during surgery, which could eliminate the need for subsequent operations. The company later introduced a second-generation, fully automated system, the Wave RPD, which could perform a complete IHC stain in 75 minutes. This technology was protected by several patents covering its rapid IHC methods.

The company successfully raised capital through several funding rounds, including a Series A in 2005, Series B in 2006 and 2009, and a Series C in 2011, totaling over $30 million in investment. However, according to at least one data source, the company is now considered deadpooled.